ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Japan approves COVID antibody cocktail used to treat Trump

Roche unit's offering holds promise as a tool against worsening cases

Then-U.S. President Donald Trump pulls off his face mask at the White House after returning from his hospitalization for COVID-19.   © Reuters

TOKYO -- An antibody cocktail developed by U.S.-based Regeneron Pharmaceuticals was granted special emergency approval by Japan's health ministry on Monday, opening up new opportunities to keep milder coronavirus cases from progressing and overwhelming health care providers on the ground.

Developed with Roche, the treatment was administered to then-U.S. President Donald Trump when he contracted COVID-19 last year. It received an emergency use authorization from the U.S. Food and Drug Administration that November.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more